Finance

Lists
Q3 2026 earnings • released • EPS miss -81.97% • Revenue miss -0.27%
See results
HIMS:NYSE
Hims & Hers Health Inc
$20.81
0.00%
(0.00) 1D
$19.80
-4.85% (-1.01)
Pre-market
Closed: Nov 11, 4:00:05 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HIMS...
Mkt. cap
4.86B
Avg. vol.
13.60M
Volume
228.69K
52-wk high
$40.99
52-wk low
$13.74
EPS
-$0.83
Beta
2.53
Shares outstanding
224.94M
No. of employees
2K
Mkt. cap
4.86B
Avg. vol.
13.60M
Volume
228.69K
52-wk high
$40.99
52-wk low
$13.74
EPS
-$0.83
Beta
2.53
Shares outstanding
224.94M
No. of employees
2K
News stories
From web sources and news partners
Profile
Hims & Hers Health, Inc., doing business as hims, is an American telehealth company headquartered in San Francisco. It provides prescription medications, over-the-counter medications, and personal care products through a direct-to-consumer subscription model. Wikipedia
About Hims & Hers Health Inc
CEO-
Employees2.44K
FoundedNov 2017
HeadquartersSan Francisco, California, United States
SectorHealth Care
IndustryHealth care provider
Website-
Analyst ratings
Based on 12 analysts giving stock ratings to HIMS in the past 3 months
Hold
Buy
3
Hold
9
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for HIMS in the last 3 months.
Highest
Current $20.81
$40.00 (+92.22%)
Average
$29.22 (+40.41%)
Lowest
$24.00 (+15.33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Justin Patterson
KeyBanc
Hold
Maintained
-
-
11/11/2026
Allen Lutz
Bank of America Securities
Hold
Maintained
-
-
11/10/2026
Michael Cherny
Leerink Partners
Hold
Maintained
$24.00
+15.3%
11/10/2026
Bryan Smilek
J.P. Morgan
Hold
Maintained
$24.00
+15.3%
11/10/2026
Mark Mahaney
Evercore ISI
Hold
Maintained
$27.00
+29.7%
11/10/2026
Brian Tanquilut
Jefferies
Hold
Maintained
$24.00
+15.3%
11/10/2026
Craig Hettenbach
Morgan Stanley
Hold
Reiterated
$25.00
+20.1%
11/10/2026
Ryan MacDonald
Needham
Buy
Reiterated
$32.00
+53.8%
11/10/2026
Maria Ripps
Canaccord Genuity
Buy
Maintained
$40.00
+92.2%
11/10/2026
David Larsen
BTIG
Hold
Maintained
-
-
11/09/2026
Glen Santangelo
Barclays
Buy
Maintained
$35.00
+68.2%
11/10/2026
Jailendra Singh
Truist Financial
Hold
Reiterated
$32.00
+53.8%
09/11/2026
George Hill
Deutsche Bank
Hold
Reiterated
$26.00
+24.9%
08/11/2026
Jonna Kim
TD Cowen
Hold
Reiterated
$30.00
+44.2%
08/11/2026
Daniel Grosslight
Citi
Hold
Maintained
$33.00
+58.6%
08/12/2026
Oliver Chen
TD Cowen
Hold
Reiterated
$25.00
+20.1%
05/12/2026
Cory Carpenter
J.P. Morgan
Buy
Maintained
$33.00
+58.6%
05/12/2026
Unknown Analyst
Nephron
Buy
Upgraded
$35.00
+68.2%
03/09/2026
Last report
Nov 10, 2026
Fiscal period
Q3 2026
$0.03 / $0.15
-81.97%miss
Revenue / Est. (USD)
890.37M / 892.77M
-0.27%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
617.82M
608.10M
753.21M
890.37M
Cost of goods sold
173.38M
182.82M
272.41M
381.17M
Cost of revenue
173.38M
182.82M
272.41M
381.17M
Research and development expenses
40.96M
46.94M
54.90M
69.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
386.64M
426.37M
521.95M
505.96M
Operating expense
427.60M
473.31M
576.85M
575.34M
Total operating expenses
600.99M
656.13M
849.26M
956.52M
Operating income
16.83M
-48.02M
-96.04M
-66.15M
Other non operating income
-575.00K
-18.58M
-2.43M
-1.22M
EBT including unusual items
18.35M
-101.55M
-92.63M
-46.25M
EBT excluding unusual items
21.56M
-61.57M
-96.22M
-67.36M
Income tax expense
-2.25M
-9.44M
-6.34M
-13.21M
Effective tax rate
-12.25%
9.29%
6.85%
28.56%
Other operating expenses
-
-
-
-
Net income
20.60M
-92.12M
-86.29M
-33.04M
Net profit margin
3.33%
-15.15%
-11.46%
-3.71%
Earnings per share
0.22
-0.19
-0.09
0.03
Interest and investment income
6.80M
7.90M
6.00M
-
Interest expense
-1.50M
-2.87M
-3.75M
-
Net interest expenses
5.30M
5.03M
2.25M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
34.92M
-26.07M
-66.57M
-27.94M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps